Daniel O'CAllaghan

Daniel O'CAllaghan

Auto-generated profile, based on publicly available information

Daniel O'CAllaghan

School of Pharmacy and Biomolecular Sciences RCSI University of Medicine and Health Sciences Dublin Ireland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
DODaniel O'CAllaghan
Daniel O'CAllaghan
HRHimanshu Rai
Himanshu Rai
DGDaniele Giacoppo
Daniele Giacoppo
JCJ. J. Coughlan
J. J. Coughlan
RDRory Durand
Rory Durand
RBRobert A. Byrne
Robert A. Byrne
Background: In patients with de novo coronary artery disease (CAD), percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation is the gold standard therapy. New evidence is available with drug coated balloons (DCB) angioplasty. The objective of this meta‐analysis was to compare the efficacy and safety of DCB angioplasty versus DES‐based PCI for patients with de novo CAD. Methods: A systematic search of PubMed, Scopus, Web of Science, and EMBASE databases was performed from January 1, 2006 up until November 1, 2024. Inclusion criteria were random treatment assignment; PCI with DCB versus DES; patients with de novo CAD; clinical follow‐up available for ≥1 year; and studies published in a peer‐reviewed journal. Trial‐level incidence rate ratios (IRR) with 95% confidence intervals (CI) were pooled by random‐effects models with inverse variance weighting. The primary outcome was major adverse cardiac events (MACE). Secondary outcomes included cardiac death, all‐cause death, and target lesion revascularization. Results: A total of nine clinical trials comprising of 4284 patients were included. The risk of the primary compositive endpoint of MACE was comparable with DCB versus DES (IRR 0.95, 95% CI 0.61 to 1.48). Secondary endpoints including cardiac death (IRR 1.49, 95% CI 0.96 to 2.33), all‐cause death (IRR 1.18, 95% CI 0.80 to 1.74), and target lesion revascularization (IRR 1.17, 95% CI 0.68 to 2.01) were comparable though CIs around treatment effects were wide. Conclusions: DCB angioplasty for de novo CAD was associated with similar medium‐term clinical outcomes compared with DES. Additional evidence is warranted in view of numerical trends in important secondary endpoints. Trial Registration: The analysis was registered at PROSPERO (CRD42024581222).

29 April 2025 in Health Science Reports
Verified
Journal Article
Open access
HRHimanshu Rai
Himanshu Rai
RRRenitha Reddi
Renitha Reddi
JCJ. J. Coughlan
J. J. Coughlan
RDRory Durand
Rory Durand
DODaniel O'CAllaghan
Daniel O'CAllaghan
RBRobert A. Byrne
Robert A. Byrne
Introduction: C‐reactive protein (CRP) is an inflammatory biomarker, implicated in the pathogenesis of atherosclerotic lesion formation, plaque rupture, and coronary thrombosis. The relationship between preprocedural CRP levels and subsequent development of in‐stent restenosis (ISR) after percutaneous coronary intervention (PCI) however remains uncertain. Against this background, we performed a systematic review and meta‐analysis, investigating the association between baseline CRP levels and the incidence of ISR after PCI. Methods: Relevant published studies were identified following a PubMed, EMBASE, MEDLINE, Scopus and Web of Knowledge databases search until April 30, 2024. To be included, studies had to be original research with: (i) angiographically determined ISR group, (ii) angiographically or clinically determined no‐ISR group, and (iii) CRP levels measured before the index PCI procedure for both groups. The mean difference in baseline CRP levels and associated 95% confidence interval (CI) between the ISR and no‐ISR groups was ascertained for each included study. The pooled standard mean difference (SMD) and its 95% CI was derived after pooling study‐level results using a random effects model, employing a Z ‐test. Begg's funnel plots and Egger's test were used for publication bias assessment. Results: Out of a total of 1018 unique results, 19 studies, with a total sample size of 4744 patients (1154 restenosis cases/3590 controls), were included for quantitative synthesis. ISR group had higher baseline CRP levels (SMD = 0.41, 95% CI = 0.16, 0.66, p = 0.001) in comparison to the no‐ISR group. No evidence of publication bias was detected either visually by Begg's funnel plots or by Egger's test ( p = 0.08). Our leave‐one‐out sensitivity analysis further attested our obtained associations. Conclusions: The present systematic review and meta‐analysis suggests a significant association of elevated pre‐PCI CRP with subsequent angiographically confirmed ISR. These results warrant further validation in dedicated large cohorts, ideally in a prospective setting.

25 March 2026 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
RDRory Durand
Rory Durand
DODaniel O’CAllaghan
Daniel O’CAllaghan
JCJ. J. Coughlan
J. J. Coughlan
SCSalvatore Cassese
Salvatore Cassese
RBRobert A. Byrne
Robert A. Byrne

12 October 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DODaniel O'CAllaghan
Daniel O'CAllaghan
HRHimanshu Rai
Himanshu Rai
DGDaniele Giacoppo
Daniele Giacoppo
JCJ.J. Coughlan
J.J. Coughlan
RCRóisín Colleran
Róisín Colleran
RBRobert A. Byrne
Robert A. Byrne

17 December 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
DODaniel O'CAllaghan
Daniel O'CAllaghan
RDRory Durand
Rory Durand
CHColm G. Hanratty
Colm G. Hanratty
TCThomas Cuisset
Thomas Cuisset
BVBeatriz Vaquerizo
Beatriz Vaquerizo
RBRobert A. Byrne
Robert A. Byrne
Introduction: Moderate‐to‐severe calcification is present in ~20%–30% of patients undergoing coronary angiography. Coronary lesion modification is often necessary to facilitate optimal stent delivery and expansion, with several dedicated devices now approved for calcium modification before stent implantation. The CYCLOPES study aims to evaluate an intravascular ultrasound (IVUS) based calcium modification algorithm for the treatment of moderate‐to‐severely calcified coronary lesions. Methods and Analysis: CYCLOPES is a prospective, international, multi‐center, observational, single‐arm study. 500 patients will be enrolled at 25 centers in Europe. Patients with planned percutaneous coronary intervention (PCI) to a native coronary artery lesion with moderate‐to‐severe calcification will be eligible. All PCI procedures will be IVUS guided, with drug‐eluting stents implanted according to the study‐specific algorithm. The co‐primary endpoints are the minimum stent area (MSA) at the site of maximum calcification at the end of the index procedure (as determined by core lab analysis), and target lesion failure (TLF) at 1‐year post‐procedure. Prespecified secondary endpoints include: the individual components of TLF at 1 month and 1 year; the MSA measured at the end of the index procedure; strategy success (defined as successful stent delivery with ≥ 80% stent expansion and complete stent apposition with no significant edge dissection and full lesion coverage with < 50% plaque burden at proximal and distal references with TIMI 3 flow); as well as target vessel revascularization; target lesion revascularization; stent thrombosis; cardiovascular death; and acute kidney injury at 1 year. Coronary angiograms and IVUS images will be analyzed by an independent core Lab. Clinical follow‐up will be performed at discharge, 30‐days, and 1 year post PCI. Trial Registration: ClinicalTrials.gov identifier: NCT06678594.

17 August 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
DODaniel O'CAllaghan
Daniel O'CAllaghan
JCJ. J. Coughlan
J. J. Coughlan
FAFernando Alfonso
Fernando Alfonso
JHJoo‐Yong Hahn
Joo‐Yong Hahn
MSManel Sabate
Manel Sabate
RBRobert A. Byrne
Robert A. Byrne
Background: In the REFORM trial, treatment of coronary in‐stent restenosis with a Biolimus A9™ drug‐coated balloon (BCB) was found to be inferior with respect to in‐segment percentage stenosis at 6‐months in comparison to treatment with a standard paclitaxel coated paclitaxel‐coated balloon (PCB). Aims: In this manuscript, the final prespecified 2‐year clinical follow up follow‐up of the REFORM trial is reported. Methods: The Prospective, Randomized, Non‐Inferiority Trial to Determine the Safety and Efficacy of the Biolimus A9™ Drug Coated Balloon for the Treatment of In‐Stent Restenosis: First‐in‐Man Trial (REFORM) was a multicenter, single blind, non‐inferiority, randomized controlled trial comparing the BCB and PCB in the treatment of coronary in‐stent restenosis (ISR). The primary angiographic endpoint of the trial was in‐segment % diameter stenosis (%DS) at 6 months, which has previously been reported. A total clinical follow‐up duration of 2 years was planned. Prespecified clinical outcomes at 2 years were: target lesion failure (TLF), target vessel failure (TVF), and their individual components. Results: At 24 months, complete follow‐up data was available for 93% ( n = 188) of the intention to treat (ITT) population. The mean age was 68.7 years, and patients were predominantly male (80.2%). Comorbidities were well balanced between the 2 groups, including diabetes mellitus, which was present in 31% of the BCB group and 29.2% of the PCB group. ISR lesions were predominantly DES‐ISR in both groups (BCB 80.7% vs. PCB 85.1%). Through to 2 year follow up, target lesion failure (TLF) occurred in 36 of 135 patients (27.8%) of patients in the BCB group and in 15 of 67 patients (23.5%) in the PCB group (HR: 1.25; 95% CI: 0.69–2.29). Clinically driven target lesion revascularization (CD‐TLR) occurred in 31 of 135 patients (24.2%) in the BCB group versus 13 of 67 patients (20.4%) in the PCB group (HR: 1.26; 95% CI: 0.66–2.40). Target vessel myocardial infarction and cardiac death were comparable in both groups. Conclusion: In patients with coronary ISR, the final 2‐year results from the REFORM study show that TLF rates were 27.8% in the biolimus‐coated balloon BCB group and 23.5% in the paclitaxel‐coated balloon PCB group. However, given the limited sample size and wide confidence intervals, the present analysis does not permit reliable inference regarding comparative event rates between treatment strategies. The results should be interpreted against the background of demonstrated inferior angiographic performance of the biolimus DCB at 6 months. Trial Registration: The trial was registered prospectively at www.clinicaltrials.gov (identifier: NCT04079192).